August 18, 2021 7:32am

Just remember it’s a “fishing game” enabling the number of variations

A “witching: option expiration on Friday

Pre-open indications:  SELLs: 1; BUYs: 7; Maintain SELL: 1

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

There is no breadline for fact and numbers-based share pricing intelligence!

My motto, never leave an investor uninformed about what I know!

Dow futures are DOWN -0.22% (-78 points), S&P futures are DOWN -0.09% (-4 point) and NASDAQ futures are also UP +0.11% (+16 points)


Stock futures are mixed, look for a shifting open on Wednesday,

European markets were slightly higher,

Asia-Pacific markets were higher as the Reserve Bank of New Zealand kept interest rates unchanged despite expectations of a hike.


Data Docket: The Federal Open Market Committee publishes its meeting minutes from its July meeting at 2 p.m. ET.

  • Mortgage rates hit their highest level in a month, and weekly demand drops. Borrowers backed away from the mortgage market last week, as higher interest rates chilled a recent revival in refinances.



On Tuesday, the major averages dipped following a decline in retail sales and the small cap benchmark Russell 2000 dropped 1.2%.


Tuesday’s evening’s recap: “a rout with a late session comeback in the cell and gene therapy sector. Indexes declined as macro factors miss estimates and Biden’s embarrassing retreat from Afghanistan could imperil legislative initiatives slowing recovery while the administration is refocusing on drug pricing reform?” …

  • The Nasdaq closed DOWN -137.58 points (-0.93%)
  • The IBB closed up +1.89% and XBI closed up +1.57%
  • Sector volume was LOW with 1 of the 21-upside having higher than the 3-month average volume with very LOW volume of 3 of 12-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.79 points or +11.110% at 17.91
  • Tuesday’s percentage (%) of the 21-upside were +0.34% (IONS) to +4.05% (ADVM) while the 12-downside -0.83% (CLBS) to -7.56% (KDNY);


  • August: 6 positive and 6 negative close
  • July: 6 positives, 1 holiday and 15 negative closes


  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes


  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday


Q2/21 Earnings releases …  … to date:


Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?

Biostage (BSTG) closed flat with 1 share traded after Monday’s -$0.22 to $1.38 with 135 share traded following Friday with 10 shares traded after Thursday and last Wednesday with 50 shares traded.

The Bottom-Line Question: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND foe a year and a half with NO clinical trial initiative … so WHAT is the value proposition WHEN they’re BROKE?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.


Pre-open Indications:


Cellectis SA (CLLS) closed down -$0.26 and has a positive +$0.26 or +2.11% pre-open indication;

CRISPR Therapeutics (CRSP) closed down -$2.00 with a positive +$0.30 or +0.25% aftermarket indication;

Editas Medicine (EDIT) closed up +$1.10 and has a positive +$0.10 or +0.16% aftermarket indication;

Intellia Therapeutics (NTLA) closed up +$0.80 and has a positive +$0.85 or +0.55% aftermarket indication;

Pluristem (PSTI) closed down -$0.22 and has a positive +$0.03 or +1.03% pre-open indication;

Sangamo Therapeutics (SGMO) closed up +$0.16 and has a positive +$0.06 or +0.62% pre-open indication;

Verastem (VSTM) closed down -$0.05 and has a positive +$0.06 or +2.25% aftermarket indication;


SELL into Strength:

Vericel (VCEL) closed up +$1.13 and has a positive +$0.37 or +0.74% aftermarket indication;


The BOTTOM LINE: the alternating cycle of being oversold is the ability to be overbought after multiple sessions

Sector Q2 earnings (26) contributed to the declining slope of many equities; so far released have been weak (3 net incomes and 23 net losses) and as usual, investors are worried that the clinical advances are in-short supply although 2024 seems to be the usual runway length and timing.

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)

Risk is no doubt increasing as we traverse through the month of August …

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is all but over … my advice, take a chance, roll the dice and then be ready to skim any new highs!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.